Seeking Alpha

The FDA has again rejected United Therapeutics' (UTHR) Treprostinil oral treatment for treating...

The FDA has again rejected United Therapeutics' (UTHR) Treprostinil oral treatment for treating for high blood pressure. United Therapeutics intends to immediately request an "end of review" meeting with the FDA to discuss the rejection. Shares -6.3% premarket. (previous) (PR)
Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)
ETF Tools
Find the right ETFs for your portfolio:
Seeking Alpha's new ETF Hub
ETF Investment Guide:
Table of Contents | One Page Summary
Read about different ETF Asset Classes:
ETF Selector

Next headline on your portfolio:

|